ATE476197T1 - Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon - Google Patents

Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon

Info

Publication number
ATE476197T1
ATE476197T1 AT04816681T AT04816681T ATE476197T1 AT E476197 T1 ATE476197 T1 AT E476197T1 AT 04816681 T AT04816681 T AT 04816681T AT 04816681 T AT04816681 T AT 04816681T AT E476197 T1 ATE476197 T1 AT E476197T1
Authority
AT
Austria
Prior art keywords
infection
encephalitis virus
japanese encephalitis
äjevü
vaccine against
Prior art date
Application number
AT04816681T
Other languages
English (en)
Inventor
Sudhanshu Vrati
Original Assignee
Nat Inst Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Inst Immunology filed Critical Nat Inst Immunology
Application granted granted Critical
Publication of ATE476197T1 publication Critical patent/ATE476197T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04816681T 2004-01-04 2004-12-30 Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon ATE476197T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1516DE2003 2004-01-04
PCT/IN2004/000432 WO2005065707A2 (en) 2004-01-04 2004-12-30 Recombinant vaccine against japanese encephalitis virus [jev] infection and a method thereof

Publications (1)

Publication Number Publication Date
ATE476197T1 true ATE476197T1 (de) 2010-08-15

Family

ID=34746657

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04816681T ATE476197T1 (de) 2004-01-04 2004-12-30 Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon

Country Status (7)

Country Link
US (2) US20070269461A1 (de)
EP (1) EP1708746B1 (de)
AT (1) ATE476197T1 (de)
AU (1) AU2004312444B2 (de)
DE (1) DE602004028512D1 (de)
HK (1) HK1094871A1 (de)
WO (1) WO2005065707A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031923A1 (de) 2014-12-11 2016-06-15 Institut Pasteur Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis
CN112979826B (zh) * 2021-03-03 2022-04-08 华中农业大学 一种乙型脑炎病毒纳米颗粒疫苗及其制备方法和应用
CN116554358A (zh) * 2023-06-26 2023-08-08 广州杰博生物科技有限公司 一种乙型脑炎疫苗及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494671A (en) * 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
PT836482E (pt) * 1995-05-24 2003-02-28 Hawaii Biotech Group Vacina subunitaria contra infeccao por flavirus

Also Published As

Publication number Publication date
EP1708746A2 (de) 2006-10-11
US20090285855A1 (en) 2009-11-19
AU2004312444B2 (en) 2010-08-12
WO2005065707B1 (en) 2005-10-27
DE602004028512D1 (de) 2010-09-16
AU2004312444A1 (en) 2005-07-21
US20070269461A1 (en) 2007-11-22
EP1708746B1 (de) 2010-08-04
WO2005065707A3 (en) 2005-08-25
WO2005065707A2 (en) 2005-07-21
HK1094871A1 (en) 2007-04-13

Similar Documents

Publication Publication Date Title
MXPA05009580A (es) Vacuna contra el virus de la influenza.
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
EP1594536A4 (de) Adjuvante influenza-vakzine
DK1090033T4 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
NO20050396L (no) Adjuvant viral partikkel
EA201170353A1 (ru) Антитела против гепатита с и их применение
WO2010047830A3 (en) Agents for hcv treatment
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
MXPA03006971A (es) Tratamiento del virus de hepatitis b.
ATE507286T1 (de) Immunisierung von fischen gegen virusinfektion
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
WO2002072803A3 (en) Subgenomic replicons of the flavivirus dengue
HK1094871A1 (en) Recombinant vaccine against japanese encephalitis virus [jev] infection and a method thereof
BR0310020A (pt) Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
EE200200157A (et) Vaktsiin
TR200202169T1 (tr) Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.
WO2007127290A3 (en) Method for producing viral vaccine and therapeutic peptide antigens
WO2004058807A3 (en) Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
DE50304603D1 (de) Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
WO2006110881A3 (en) Yersinia polypeptide vaccines, antibodies and immunomodulatory proteins
NO20042124L (no) Thymosinforsterkning ved genetisk immunisering
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
RU2004104357A (ru) Вакцинный состав, потенцированный комбинацией днк и антигена

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties